Zimmer Biomet beats by $0.03, reports revs in-line; guides FY17 EPS in-line, revs in-line
- Reports Q4 (Dec) earnings of $2.14 per share, $0.03 better than the Capital IQ Consensus of $2.11; revenues rose 4.1% year/year to $2.01 bln vs the $2.01 bln Capital IQ Consensus.
- Co issues in-line guidance for FY17, sees EPS of $8.50-8.68 vs. $8.65 Capital IQ Consensus Estimate; sees FY17 revs of $7.855-7.930 bln vs. $7.91 bln Capital IQ Consensus Estimate.
- "As we reflect on the completion of our first full year as a combined company, our achievements have further strengthened our confidence in the unique value-creation opportunity we offer in the dynamic global healthcare environment. We will continue to drive growth across our broad musculoskeletal portfolio in 2017, as we remain focused on delivering against our net synergy commitments and making ongoing progress towards optimizing and harmonizing our supply chain, and manufacturing and quality systems.